BRIEF-EMA Gets Application For Conditional Marketing Authorisation...

From EU COST Fin-AI
Jump to navigation Jump to search


Jan 12 (Reuters) - European Medicines Agency:

* EMA SAYS RECEIVED AN APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION (CMA) FOR A COVID-19 VACCINE DEVELOPED BY ASTRAZENECA AND OXFORD UNIVERSITY

* ASSESSMENT OF THE VACCINE, KNOWN AS COVID-19 VACCINE ASTRAZENECA, WILL PROCEED UNDER AN ACCELERATED TIMELINE

* ASSESSMENT OF VACCINE, panel pulsa termurah KNOWN AS COVID-19 VACCINE ASTRAZENECA, WILL PROCEED UNDER AN ACCELERATED TIMELINE

* EMA SAYS AN OPINION ON MARKETING AUTHORISATION COULD BE ISSUED BY 29 JANUARY DURING MEETING OF EMA'S SCIENTIFIC COMMITTEE FOR HUMAN MEDICINES (CHMP)

* ADDITIONAL SCIENTIFIC INFO ON ISSUES RELATED TO QUALITY, SAFETY, EFFICACY OF VACCINE PROVIDED BY ASTRAZENECA AT REQUEST OF CHMP, CURRENTLY BEING ASSESSED Source text: website Further company coverage:

Retrieved from "https://wiki.fin-ai.eu/index.php?title=BRIEF-EMA_Gets_Application_For_Conditional_Marketing_Authorisation...&oldid=3497"